24 completed, 8 recruiting, 4 active not recruiting, 4 unknown. 12 Phase 2, 5 Phase 1, 4 Phase 3, 3 Phase 4, 1 Not applicable.
Follow Hypophosphatasia: new trials by email Literature Review of Hypophosphatasia trials Research Report on Hypophosphatasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clarify HPP: Disease Burden of HPP Patients in China Hypophosphatasia (HPP) | Recruiting | AstraZeneca | 200 | 2026-09-26 | 2026-10-29 | |
| GRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP) AGN1 LOEP - Osteoporosis | Enrolling by invitation | AgNovos Healthcare, LLC | 305 | 2026-08-25 | 2026-10-30 | |
| Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia methotrexate, rituximab, bortezomib - Hypophosphatasia | Phase 4 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2026-07-29 | 2025-12-18 | |
| The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia Hypophosphatasia | Recruiting | AstraZeneca | 55 | 2025-12-29 | 2026-09-28 | |
| A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1 ALE1, Placebo - Hypophosphatasia (HPP) | Phase 1 / Phase 2 | Recruiting | Alesta Therapeutics | 120 | 2025-09-30 | 2026-08-03 |
| Characteristics of Hypophosphatasia in Adult Patients in Rheumatology and Their Value in Developing an Algorithm to HPP-diagnosis - the COHIR Multi-center Study Second alkaline phosphatase measurement - Hypophosphatasia | Recruiting | University of Bonn | 720 | 2024-08-25 | 2025-02-10 | |
| Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP ALXN1850, Placebo - Hypophosphatasia | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 30 | 2024-05-14 | 2026-05-28 |
| Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa ALXN1850, asfotase alfa - Hypophosphatasia | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 43 | 2024-04-02 | 2026-05-05 |
| Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa ALXN1850, Placebo - Hypophosphatasia | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 124 | 2024-01-03 | 2026-06-22 |
| Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia Ilofotase Alfa, 0.8 mg/kg, Ilofotase Alfa, 3.2 mg/kg - Hypophosphatasia | Phase 1 / Phase 2 | Completed | AM-Pharma | 12 | 2023-05-15 | 2025-02-27 |
| Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO) Data collection - Hypophosphatasia | Recruiting | Assistance Publique - Hôpitaux de Paris | 200 | 2023-03-22 | 2026-08-05 | |
| Characteristics of Hypophosphatasia in Adult Patients in Rheumatology Second alkaline phosphatase measurement, Extended laboratory diagnostics, Symptom and clinical findings checklist for hypophosphatasia - Hypophosphatasia | Unknown | University of Bonn | 60 | 2023-02-28 | 2023-12-07 | |
| A Prospective Sub-Study of the Global Hypophosphatasia Registry Asfotase Alfa - Hypophosphatasia | Recruiting | Alexion Pharmaceuticals, Inc. | 30 | 2022-08-25 | 2026-02-09 | |
| Study of ALXN1850 in Participants With Hypophosphatasia (HPP) ALXN1850 - Hypophosphatasia | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 15 | 2021-09-28 | 2024-12-27 |
| United States Hypophosphatasia Molecular Research Center Whole Genome Sequencing - Hypophosphatasia | Completed | Children's Mercy Hospital Kansas City | 29 | 2021-08-24 | 2026-05-19 | |
| The PORTRAIT Study Hypophosphatasia | Unknown | Sheffield Teaching Hospitals NHS Foundation Trust | 14 | 2021-07-12 | 2022-11-02 | |
| Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) Hypophosphatasia | Completed | CENTOGENE GmbH Rostock | 16 | 2021-06-02 | 2021-12-29 | |
| Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease asfotase alfa - Hypophosphatasia | Phase 4 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2020-04-01 | 2020-06-04 | |
| Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa) asfotase alfa - Hypophosphatasia | Completed | Alexion Pharmaceuticals, Inc. | 50 | 2019-11-06 | 2024-07-10 | |
| Evaluation of Bone Architecture and Bone Strength in Adults With Hypophosphatasia (HPP) Microindentation, High resolution peripheral quantitative computed tomography (HRpQCT), Biochemical analysis of different bone markers. - Hypophosphatasia (HPP) | Unknown | Hvidovre University Hospital | 30 | 2019-10-01 | 2021-09-01 |
Showing 20 of 46. Sign in to see all of them.
Osteomalacia (13) · Rickets (13) · Bone Diseases (12) · Bone Diseases, Metabolic (3) · Rare Diseases (3) · Ataxia with vitamin E deficiency (2) · Cystinosis (2) · Genetic Diseases, Inborn (2) · Hyperargininemia (2) · Leukodystrophy, Metachromatic (2) · Multiple Endocrine Neoplasia Type 2b (2) · Pitt-Hopkins syndrome (2) · Stickler syndrome, type 1 (2) · Stickler syndrome, type 2 (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (46) · Metabolic Diseases (46) · Metabolism, Inborn Errors (46) · Metal Metabolism, Inborn Errors (46) · Nutritional and Metabolic Diseases (46) · Genetic Diseases, Inborn (44) · Musculoskeletal Diseases (20) · Bone Diseases, Metabolic (16) · Avitaminosis (15) · Deficiency Diseases (15) · Malnutrition (15) · Nutrition Disorders (15) · Calcium Metabolism Disorders (14) · Vitamin D Deficiency (14) · Bone Diseases (7)
asfotase alfa (16) · Bortezomib (1) · Data Collection (1) · Folic Acid (1) · Immunoglobulins, Intravenous (1) · Methotrexate (1) · MicroRNAs (1) · Physical Examination (1) · Rituximab (1) · Whole Genome Sequencing (1) · setrusumab (1)
Alexion Pharmaceuticals, Inc. (23) · Sheffield Teaching Hospitals NHS Foundation Trust (3) · AstraZeneca (2) · University of Bonn (2) · AM-Pharma (1) · AgNovos Healthcare, LLC (1) · Alesta Therapeutics (1) · Assistance Publique - Hôpitaux de Paris (1) · CENTOGENE GmbH Rostock (1) · Children's Mercy Hospital Kansas City (1) · Dr. Lothar Seefried (1) · Duke University (1) · Emine Hafize (1) · Hvidovre University Hospital (1) · Medical University of Vienna (1)
United States (23) · Germany (13) · United Kingdom (13) · Canada (12) · Australia (7) · France (6) · Spain (5) · Turkey (Türkiye) (5) · Japan (4) · China (3) · Italy (3) · Poland (3) · Russia (3) · Taiwan (3) · Argentina (2)
Andrew Denker, MD, PhD (1) · Curt Scharfe, MD, PhD (1) · Eric Rush (1) · Keiichi Ozono (1) · Kenji Fujita, MD (1) · Lothar Seefried, MD (1) · Michael P. Whyte, MD (1) · Peter Bauer, Prof. Dr. (1) · Priya Kishnani, MD (1) · Richard Eastell (1) · Richard Eastell, MD (1) · Richard Eastell, MD FRCP (1)
PMID 26529632, PMID 32417537, PMID 32762706, PMID 27699270, PMID 22397652, PMID 28436937, PMID 30558909, PMID 30811537, PMID 30969260, PMID 31315600, PMID 32987199, PMID 33822385, PMID 35142618, PMID 36054522, PMID 37481150, PMID 39135540, PMID 39276275, PMID 39930630, PMID 41378916